{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T22:31:22Z","timestamp":1766269882168,"version":"3.41.2"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Prostate cancer (PCa) is one of the most prevalent malignancies affecting males; however, the role of inflammatory activity in the pathogenesis of this disease is not yet fully elucidated. Although inflammation is recognized as being closely associated with the onset and progression of PCa, the specific causal relationships between individual inflammatory factors and the disease require further clarification.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Mendelian randomization (MR) methodologies can mitigate bias by utilizing whole-genome sequencing data, leveraging specific genetic variants to assess causal relationships between a given exposure and an outcome of interest. This research employed an MR approach to investigate the association between inflammatory cytokines and PCa.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 44 inflammatory cytokines were evaluated in a large GWAS dataset to enable the drawing of robust conclusions. Elevated circulating C-reactive protein (CRP) and prostaglandin E2 (PGE-2) levels were related to greater PCa risk. The reverse Mendelian randomization (MR) study indicates a causal relationship between prostate cancer and stem cell factor (SCF) (<jats:italic>P<\/jats:italic>=0.025).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>CRP and PGE-2 play crucial roles in the regulation of PCa development. Moreover, PCa may have an impact on SCF levels. Further research is imperative to elucidate whether these biomarkers can be effectively utilized to prevent or treat PCa.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1381803","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T04:10:38Z","timestamp":1724904638000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Exploration of the causal relationship between inflammatory cytokines and prostate carcinoma: a comprehensive Mendelian randomization study"],"prefix":"10.3389","volume":"14","author":[{"given":"Xianfu","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Decai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenguang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wujun","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp2209151","article-title":"Screening for prostate cancer","volume":"388","author":"Pinsky","year":"2023","journal-title":"New Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.3390\/biomedicines11123140","article-title":"Inflammation in prostate cancer: exploring the promising role of phenolic compounds as an innovative therapeutic approach","volume":"11","author":"Fernandes","year":"2023","journal-title":"Biomedicines"},{"key":"B3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.nucmedbio.2019.01.003","article-title":"Prostate cancer and inflammation: A new molecular imaging challenge in the era of personalized medicine","author":"Schillaci","year":"2019","journal-title":"Nucl Med Biol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3390\/toxins10110436","article-title":"Evaluation of aflatoxin M1 effects on the metabolomic and cytokinomic profiling of a hepatoblastoma cell line","volume":"10","author":"Marchese","year":"2018","journal-title":"Toxins"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/pros.21020","article-title":"Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+","volume":"69","author":"Sfanos","year":"2009","journal-title":"Prostate"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09804.x","article-title":"Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer","volume":"107","author":"Nonomura","year":"2011","journal-title":"BJU Int"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-12-30","article-title":"Tumor infiltrating B-cells are increased in prostate cancer tissue","volume":"12","author":"Woo","year":"2014","journal-title":"J Trans Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.3390\/ijms20051069","article-title":"HBD inhibits the development of colitis-associated cancer in mice via the IL-6R\/STAT3 signaling pathway","volume":"20","author":"Deng","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-0348-0837-8_7","article-title":"The role of inflammation in prostate cancer","volume":"816","author":"Sfanos","year":"2014","journal-title":"Adv Exp Med Biol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.21037\/tau-23-55","article-title":"Inflammation-related indicators have a potential to increase overall quality of the prostate cancer management: a narrative review","volume":"12","author":"Zhou","year":"2023","journal-title":"Trans Androl Urol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-015-0011-z","article-title":"Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors","volume":"30","author":"Burgess","year":"2015","journal-title":"Eur J Epidemiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ajhg.2016.11.007","article-title":"Genome-wide association study identifies 27 loci influencing concentrations of circulating cytokines and growth factors","volume":"100","author":"Ahola-Olli","year":"2017","journal-title":"Am J Hum Genet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.17219","article-title":"Mendelian randomization","volume":"318","author":"Emdin","year":"2017","journal-title":"Jama"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/0962280210394459","article-title":"Using multiple genetic variants as instrumental variables for modifiable risk factors","volume":"21","author":"Palmer","year":"2012","journal-title":"Stat Methods Med Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyq151","article-title":"Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants","volume":"40","author":"Pierce","year":"2011","journal-title":"Int J Epidemiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btv402","article-title":"LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants","volume":"31","author":"Machiela","year":"2015","journal-title":"Bioinf (Oxford England)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-021-00954-4","article-title":"A generalized linear mixed model association tool for biobank-scale data","volume":"53","author":"Jiang","year":"2021","journal-title":"Nat Genet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/gepi.21758","article-title":"Mendelian randomization analysis with multiple genetic variants using summarized data","volume":"37","author":"Burgess","year":"2013","journal-title":"Genet Epidemiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/gepi.21965","article-title":"Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator","volume":"40","author":"Bowden","year":"2016","journal-title":"Genet Epidemiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv080","article-title":"Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression","volume":"44","author":"Bowden","year":"2015","journal-title":"Int J Epidemiol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0099-7","article-title":"Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases","volume":"50","author":"Verbanck","year":"2018","journal-title":"Nat Genet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.34408","article-title":"The MR-Base platform supports systematic causal inference across the human phenome","volume":"7","author":"Hemani","year":"2018","journal-title":"Elife"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.597420","article-title":"Causal evaluation of laboratory markers in type 2 diabetes on cancer and vascular diseases using various mendelian randomization tools","volume":"11","author":"Jin","year":"2020","journal-title":"Front Genet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1162820","article-title":"Combination of C-reactive protein\/albumin ratio and time to castration resistance enhances prediction of prognosis for patients with metastatic castration-resistant prostate cancer","volume":"13","author":"Mitsui","year":"2023","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1111277","article-title":"C-reactive protein levels could be a prognosis predictor of prostate cancer: A meta-analysis","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Endocrinol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"12968","DOI":"10.3390\/ijms232112968","article-title":"Old and new blood markers in human colorectal cancer","volume":"23","author":"Wautier","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s13046-020-01709-5","article-title":"The role of microenvironment in tumor angiogenesis","volume":"39","author":"Jiang","year":"2020","journal-title":"J Exp Clin Cancer Res: CR"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2010.482207","article-title":"Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression","volume":"10","author":"Whiteside","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.3390\/cancers13133263","article-title":"Melatonin as an adjuvant to antiangiogenic cancer treatments","volume":"13","author":"Gonz\u00e1lez","year":"2021","journal-title":"Cancers"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2016010098","article-title":"Mendelian randomization as an approach to assess causality using observational data","volume":"27","author":"Sekula","year":"2016","journal-title":"J Am Soc Nephrol: JASN"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2023.2285785","article-title":"The anti-inflammatory and vasoprotective properties of mPGES-1 inhibition offer promising therapeutic potential","volume":"27","author":"Steinmetz-Sp\u00e4h","year":"2023","journal-title":"Expert Opin Ther Targets"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.13.7220","article-title":"Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target","volume":"96","author":"Jakobsson","year":"1999","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.3390\/cells11162528","article-title":"The interaction of human papillomavirus infection and prostaglandin E2 signaling in carcinogenesis: A focus on cervical cancer therapeutics","volume":"11","author":"Garc\u00eda-Quiroz","year":"2022","journal-title":"Cells"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.791696","article-title":"The prostaglandin E2 pathway and breast cancer stem cells: evidence of increased signaling and potential targeting","volume":"11","author":"Walker","year":"2021","journal-title":"Front Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1995.tb32318.x","article-title":"Do post-transcriptional mechanisms participate in induction of C-reactive protein and serum amyloid A by IL-6 and IL-1","volume":"762","author":"Kushner","year":"1995","journal-title":"Ann New York Acad Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.12.7019","article-title":"C-reactive protein mediates protection from lipopolysaccharide through interactions with Fc\u03b3R","volume":"169","author":"Mold","year":"2002","journal-title":"J Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.11.5792","article-title":"Experimental allergic encephalomyelitis is inhibited in transgenic mice expressing human C-reactive protein","volume":"168","author":"Szalai","year":"2002","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-023-03290-5","article-title":"Prognostic and clinicopathological significance of C-reactive protein in patients with ovarian cancer: a meta-analysis","volume":"22","author":"Zhang","year":"2024","journal-title":"World J Surg Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.721989","article-title":"The role of C-reactive protein in kidney, bladder, and prostate cancers","volume":"12","author":"O\u2019Brian","year":"2021","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.3390\/cells10061487","article-title":"The role of prostaglandins in different types of cancer","volume":"10","author":"Jara-Guti\u00e9rrez","year":"2021","journal-title":"Cells"},{"key":"B41","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s12916-022-02506-x","article-title":"C-reactive protein and cancer risk: a pan-cancer study of prospective cohort and Mendelian randomization analysis","volume":"20","author":"Zhu","year":"2022","journal-title":"BMC Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3850","article-title":"Growth and differentiation factor 15 and NF-\u03baB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection","volume":"10","author":"Rybicki","year":"2021","journal-title":"Cancer Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and cancer: triggers, mechanisms, and consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.27.0454","article-title":"C-reactive protein and risk of lung cancer","volume":"28","author":"Chaturvedi","year":"2010","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2017.08.008","article-title":"Genetic and environmental influences on stability and change in baseline levels of C-reactive protein: A longitudinal twin study","volume":"265","author":"Sas","year":"2017","journal-title":"Atherosclerosis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.21.9410","article-title":"Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers","volume":"27","author":"Antonarakis","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1381803\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T04:10:41Z","timestamp":1724904641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1381803\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":46,"alternative-id":["10.3389\/fonc.2024.1381803"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1381803","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2024,8,29]]},"article-number":"1381803"}}